AU2016210548B2 - Cytomegalovirus antigens and uses thereof - Google Patents

Cytomegalovirus antigens and uses thereof Download PDF

Info

Publication number
AU2016210548B2
AU2016210548B2 AU2016210548A AU2016210548A AU2016210548B2 AU 2016210548 B2 AU2016210548 B2 AU 2016210548B2 AU 2016210548 A AU2016210548 A AU 2016210548A AU 2016210548 A AU2016210548 A AU 2016210548A AU 2016210548 B2 AU2016210548 B2 AU 2016210548B2
Authority
AU
Australia
Prior art keywords
leu
val
pro
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016210548A
Other languages
English (en)
Other versions
AU2016210548A1 (en
Inventor
Andrea Carfi
Claudio CIFERRI
Yi Xing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2016210548A1 publication Critical patent/AU2016210548A1/en
Priority to AU2018226521A priority Critical patent/AU2018226521B2/en
Application granted granted Critical
Publication of AU2016210548B2 publication Critical patent/AU2016210548B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016210548A 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof Ceased AU2016210548B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018226521A AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152221.6 2015-01-22
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof
PCT/IB2016/050335 WO2016116904A1 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018226521A Division AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Publications (2)

Publication Number Publication Date
AU2016210548A1 AU2016210548A1 (en) 2017-08-10
AU2016210548B2 true AU2016210548B2 (en) 2018-11-08

Family

ID=52434568

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016210548A Ceased AU2016210548B2 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof
AU2018226521A Ceased AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018226521A Ceased AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Country Status (24)

Country Link
US (2) US10167321B2 (enExample)
EP (3) EP3048114A1 (enExample)
JP (1) JP6717836B2 (enExample)
KR (1) KR20170100039A (enExample)
CN (1) CN107531761B (enExample)
AU (2) AU2016210548B2 (enExample)
BE (1) BE1023087B1 (enExample)
BR (1) BR112017015567A2 (enExample)
CA (1) CA2974041C (enExample)
DK (1) DK3247722T5 (enExample)
EA (1) EA038250B1 (enExample)
ES (1) ES2937959T3 (enExample)
FI (1) FI3247722T3 (enExample)
HR (1) HRP20230177T1 (enExample)
HU (1) HUE061175T2 (enExample)
IL (1) IL253366B (enExample)
LT (1) LT3247722T (enExample)
MX (1) MX382518B (enExample)
PL (1) PL3247722T3 (enExample)
PT (1) PT3247722T (enExample)
SG (1) SG11201705740UA (enExample)
SI (1) SI3247722T1 (enExample)
WO (1) WO2016116904A1 (enExample)
ZA (1) ZA201704912B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN113528466B (zh) 2014-07-16 2024-12-24 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
SG11201706454VA (en) 2015-02-10 2017-09-28 Univ Oregon Health & Science Methods and compositions useful in generating non canonical cd8+ t cell responses
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
CN108474003A (zh) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
WO2018067580A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
BR112019007982A2 (pt) 2016-10-18 2019-07-02 Univ Oregon Health & Science vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US11773144B2 (en) 2017-10-02 2023-10-03 Duke University Mosaic HIV-1 envelopes to induce ADCC responses
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN118580343B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005959A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
CA2654563A1 (en) 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP2352759B1 (en) * 2008-07-16 2017-11-01 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
ES2649896T3 (es) 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
CA2814386C (en) 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
US20150359879A1 (en) * 2012-10-30 2015-12-17 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
MX373329B (es) 2013-12-20 2020-05-21 Novartis Ag Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
LT3083676T (lt) 2013-12-20 2019-11-25 Novartis Ag Naujos eukariotinės ląstelės, ir dominančio polipeptido rekombinantinės raiškos būdai
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005959A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLAUDIO CIFERRI ET AL, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2015-01-26), vol. 112, no. 6, doi:10.1073/pnas.1424818112, ISSN 0027-8424, pages 1767 - 1772 *
RYCKMAN BRENT J ET AL,, JOURNAL OF VIROLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 1, doi:10.1128/JVI.01910-07, ISSN 1098-5514, (2008-01-01), pages 60 - 70, (2007-10-17) *
WEN YINGXIA ET AL, , VACCINE, ELSEVIER LTD, GB, (2014-05-14), vol. 32, no. 30, doi:10.1016/J.VACCINE.2014.05.004, ISSN 0264-410X, pages 3796 - 3804 *

Also Published As

Publication number Publication date
EA038250B1 (ru) 2021-07-29
SG11201705740UA (en) 2017-08-30
DK3247722T5 (da) 2024-10-07
EP3247722A1 (en) 2017-11-29
IL253366B (en) 2022-03-01
CN107531761B (zh) 2022-01-14
AU2018226521A1 (en) 2018-09-27
EP3247722B1 (en) 2022-11-30
JP6717836B2 (ja) 2020-07-08
CA2974041A1 (en) 2016-07-28
CN107531761A (zh) 2018-01-02
ES2937959T3 (es) 2023-04-03
AU2018226521B2 (en) 2019-10-31
WO2016116904A1 (en) 2016-07-28
LT3247722T (lt) 2023-02-10
FI3247722T3 (fi) 2023-03-17
PT3247722T (pt) 2023-01-31
US20190276498A1 (en) 2019-09-12
BE1023087A1 (fr) 2016-11-18
SI3247722T1 (sl) 2023-04-28
BR112017015567A2 (pt) 2018-03-13
EP4180056A1 (en) 2023-05-17
BE1023087B1 (fr) 2016-11-18
HUE061175T2 (hu) 2023-05-28
IL253366A0 (en) 2017-09-28
AU2016210548A1 (en) 2017-08-10
CA2974041C (en) 2023-04-04
DK3247722T3 (da) 2023-01-30
MX382518B (es) 2025-03-13
JP2018504117A (ja) 2018-02-15
ZA201704912B (en) 2018-12-19
KR20170100039A (ko) 2017-09-01
US10167321B2 (en) 2019-01-01
HRP20230177T1 (hr) 2023-04-14
MX2017009538A (es) 2017-11-02
US20170369532A1 (en) 2017-12-28
PL3247722T3 (pl) 2023-03-20
EP3048114A1 (en) 2016-07-27
EA201791562A1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
AU2018226521B2 (en) Cytomegalovirus antigens and uses thereof
CA2931853C (en) Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines
EP3031822A1 (en) Cytomegalovirus antigens
US20210346492A1 (en) SARS-CoV-2 Vaccines
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
CN113151184A (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
US20170119874A1 (en) Human cytomegalovirus vaccine compositions and method of producing the same
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
US20250026793A1 (en) Chimeric betacoronavirus spike polypeptides
HK40087930A (en) Cytomegalovirus antigens and uses thereof
KR100845192B1 (ko) Ｇｍ-음성 ｅｈｖ-돌연변이
WO2023179514A1 (zh) 冠状病毒疫苗组合物、方法及其使用
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
WO2023179513A1 (zh) 冠状病毒疫苗组合物、方法及其使用
WO2023047349A1 (en) Stabilized coronavirus spike protein fusion proteins
CN116685347A (zh) 编码嵌合冠状病毒刺突蛋白的重组载体及其用途
WO2023047348A1 (en) Stabilized corona virus spike protein fusion proteins
JP2023549787A (ja) キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
TW202320845A (zh) 用於預防及治療２０１９冠狀病毒病（ＣＯＶＩＤ—１９）之ＳＡＲＳ—ＣｏＶ—２多重表位肽／蛋白質疫苗
Wang Expression and Characterization of SARS Spike and Nucleocapsid Proteins and Their Fragments in Baculovirus and E. coli
Lucy Kuo et al. A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly
HK1012415B (en) Fusion glycoprotein from hcmv and hsv
HK1012415A1 (en) Fusion glycoprotein from hcmv and hsv

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired